Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer.
Haoran FengKun LiuXiaonan ShenJuyong LiangChanggang WangWeihua QiuXi ChengRen ZhaoPublished in: Cell death & disease (2020)
A Correction to this paper has been published: https://doi.org/10.1038/s41419-020-03208-z.